Online inquiry

IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15427MR)

This product GTTS-WQ15427MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15427MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7971MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ15252MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ5244MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ5605MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP791
GTTS-WQ10896MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ1967MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGS-15E
GTTS-WQ2186MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ1456MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW